Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A Kunitz-type protease inhibitor, bikunin, downregulates expression of uPA and its receptor uPAR at the mRNA and protein levels in several types of tumor cells. Our recent work showed that, using a cDNA microarray analysis,
pregnancy-associated plasma protein-A
(
PAPP-A
) is a candidate bikunin target gene. To clarify how reduced levels of
PAPP-A
may confer repressed invasiveness, we transfected human ovarian cancer cell line HRA with antisense (AS)-
PAPP-A
cDNA and compared the properties of the transfected cells to those of parental HRA cells. Here, we show that regulation of uPA mRNA and protein by IGF-I depends on the PI3K and
MAPK
signaling pathways and phosphorylation of Akt and
ERK1
/2 is required for IGF-I-mediated cell invasion; that IGFBP-4 protease in HRA cells is identified as
PAPP-A
; that reduced
PAPP-A
expression is associated with the upregulation of IGFBP-4 expression; that higher intact IGFBP-4 levels were associated with low invasive potential and growth rate in AS-
PAPP-A
cells in response to IGF-I; that IGF-I stimulates Akt and
ERK1
/2 activation of both the control and antisense cells, but the relative potency and efficacy of IGF-I were lower in the antisense cells compared to the control; and that genetic downregulation of
PAPP-A
reduces the proliferation, invasion and metastasis of HRA cells. In conclusion, our data identify a novel role for
PAPP-A
as a bikunin target gene. IGF-I-induced IGFBP-4 proteolysis by
PAPP-A
may enhance cell growth and invasion through IGF-I-dependent Akt and
ERK1
/2 activation and subsequently upregulation of uPA.
...
PMID:Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis. 1496 70